迪臣建設(08268.HK)擬1060萬港元出售香港商業物業
格隆匯10月24日丨迪臣建設(08268.HK)宣佈,於2019年10月24日,公司間接全資附屬New Stream Holdings Limited作為賣方與一名獨立第三方訂立買賣協議,據此賣方同意向其出售Rosy Beauty Investments Limited全部已發行股份及相關債務,總代價為現金1060萬港元。
目標公司主要從事投資控股及物業投資,其單獨持有位於香港駱克道401–403號榮華商業大廈的半層物業。該物業為商業辦公室,總物業面積約為681平方尺。該物業位處香港黃金地段,鄰近灣仔港鐵站及銅鑼灣港鐵站。該物業由賣方於2018年6月以代價1030萬港元購入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.